[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100452498":3},{"organization":4,"armGroups":7,"interventions":46,"overallOfficials":55,"centralContacts":60,"locations":65,"responsibleParty":80,"collaborators":10,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":10,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":10,"maxAge":10,"enrollmentInfo":90,"targetDuration":93,"studyType":94,"phases":10,"briefSummary":95,"conditions":96,"keywords":10,"overallStatus":98,"whyStopped":10,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","OTHER",[8,13,16,19,22,25,28,31,34,37,40,43],{"label":9,"type":10,"description":10,"interventionNames":11},"Psoriasis",null,[12],"Other: Questionnaires",{"label":14,"type":10,"description":10,"interventionNames":15},"Psoriatic arthritis",[12],{"label":17,"type":10,"description":10,"interventionNames":18},"Atopic dermatitis",[12],{"label":20,"type":10,"description":10,"interventionNames":21},"Chronic urticaria",[12],{"label":23,"type":10,"description":10,"interventionNames":24},"Suppurative hydrosadenitis",[12],{"label":26,"type":10,"description":10,"interventionNames":27},"Systemic lupus erythematosus",[12],{"label":29,"type":10,"description":10,"interventionNames":30},"Acne vulgaris",[12],{"label":32,"type":10,"description":10,"interventionNames":33},"Rosacea",[12],{"label":35,"type":10,"description":10,"interventionNames":36},"Seborrheic dermatitis",[12],{"label":38,"type":10,"description":10,"interventionNames":39},"Contact dermatitis",[12],{"label":41,"type":10,"description":10,"interventionNames":42},"Chronic eczema of the hands",[12],{"label":44,"type":10,"description":10,"interventionNames":45},"Vitiligo",[12],[47],{"type":6,"name":48,"description":49,"armGroupLabels":50,"otherNames":51},"Questionnaires","This is a collection of data from normal clinical routine: patients will be asked to record the assessments they undergo during their course of treatment, without changing clinical practice in any way. Data inherent to the following procedures will be collected: examinations, laboratory tests, imaging tests, questionnaires and rating scales.",[29,17,41,20,38,9,14,32,35,23,26,44],[52,53,54],"blood tests","instrumental and\u002For imaging examinations","rating scales",[56],{"name":57,"affiliation":58,"role":59},"Giovanni Damiani, Dr.","IRCSS Ortopedico Galeazzi","PRINCIPAL_INVESTIGATOR",[61],{"name":57,"role":62,"phone":63,"phoneExt":10,"email":64},"CONTACT","393929403679","dr.giovanni.damiani@gmail.com",[66],{"facility":67,"status":10,"city":68,"state":10,"zip":69,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":77,"contacts":78},"IRCCS Istituto Ortopedico Galeazzi","Milan","20161","Italy","IT",{"type":73,"coordinates":74},"Point",[75,76],9.18951,45.46427,{"lat":76,"lon":75},[79],{"name":57,"role":62,"phone":10,"phoneExt":10,"email":10},{"type":81,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100452498","registry-and-monitoring-of-immune-mediated-inflammatory-diseases-100452498",false,"NCT05172284","Registry and Monitoring of ImmuNe-mediated Inflammatory Diseases","Registry and Monitoring of ImmuNe-mediated Inflammatory Diseases (IMIDs) REMIND Study","Inclusion Criteria:\n\n* Patients with a diagnosis of IMID.\n* Patients of any age, including minors.\n* Patients treated with approved medications for the condition in question and\u002For phototherapy.\n* Patients who agree to sign informed consent.\n\nExclusion Criteria:\n\n* Patients without a diagnosis of IMID.\n* Patients who do not consent to sign informed consent.","ALL",{"count":91,"type":92},2000,"ESTIMATED","15 Years","OBSERVATIONAL","Formation of a registry of IMID patients to assess the evolution of resistance to conventional and target therapies. This aim is achieved by evaluating the achievement of PASI 50 and PASI 75 scores at week 16 from the start of treatment.",[97],"ImmuNe-Mediated Inflammatory Diseases","NOT_YET_RECRUITING","2022-01-10",{"date":101,"type":102},"2022-01-11","ACTUAL",{"date":104,"type":92},"2022-02",{"date":106,"type":92},"2026-12",{"name":5,"class":6},1]